S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Better Than Oil Stocks (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
Elon Musk's "Project Dojo" is a Game-Changer (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
Elon Musk's "Project Dojo" is a Game-Changer (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Better Than Oil Stocks (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
Elon Musk's "Project Dojo" is a Game-Changer (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
Elon Musk's "Project Dojo" is a Game-Changer (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Better Than Oil Stocks (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
Elon Musk's "Project Dojo" is a Game-Changer (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
Elon Musk's "Project Dojo" is a Game-Changer (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Better Than Oil Stocks (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
Elon Musk's "Project Dojo" is a Game-Changer (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
Elon Musk's "Project Dojo" is a Game-Changer (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
NYSE:PBH

Prestige Consumer Healthcare (PBH) Stock Price, News & Analysis

$69.72
+0.32 (+0.46%)
(As of 02/23/2024 ET)
Today's Range
$69.41
$70.00
50-Day Range
$58.76
$69.72
52-Week Range
$55.96
$70.00
Volume
167,680 shs
Average Volume
267,550 shs
Market Capitalization
$3.46 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$110.00

Prestige Consumer Healthcare MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
57.8% Upside
$110.00 Price Target
Short Interest
Bearish
3.51% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.35
Upright™ Environmental Score
News Sentiment
1.17mentions of Prestige Consumer Healthcare in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$368,184 Sold Last Quarter
Proj. Earnings Growth
6.47%
From $4.33 to $4.61 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.17 out of 5 stars

Medical Sector

155th out of 943 stocks

Pharmaceutical Preparations Industry

64th out of 430 stocks


PBH stock logo

About Prestige Consumer Healthcare Stock (NYSE:PBH)

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.

PBH Stock Price History

PBH Stock News Headlines

PBH Mar 2024 55.000 put
PBH Jul 2024 70.000 call
Elon Musk's "Project Dojo" is a Game-Changer
Morgan Stanley predicts that Musk's latest act will boost Tesla's shares by 80% in the next 12 months. But if you want to profit from this development, you'll buy the firm that could see its sales explode by 829% as "Project Dojo" sweeps the nation.
Elon Musk's "Project Dojo" is a Game-Changer
Morgan Stanley predicts that Musk's latest act will boost Tesla's shares by 80% in the next 12 months. But if you want to profit from this development, you'll buy the firm that could see its sales explode by 829% as "Project Dojo" sweeps the nation.
Prestige Consumer Healthcare: Fiscal Q3 Earnings Snapshot
Should You Invest in Prestige Consumer Healthcare (PBH)?
See More Headlines
Receive PBH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Prestige Consumer Healthcare and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/08/2024
Today
2/24/2024
Fiscal Year End
3/31/2024
Next Earnings (Estimated)
5/02/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Personal Products
CUSIP
74112D10
Employees
560
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$110.00
High Stock Price Target
$117.00
Low Stock Price Target
$103.00
Potential Upside/Downside
+57.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-82,310,000.00
Pretax Margin
-8.01%

Debt

Sales & Book Value

Annual Sales
$1.13 billion
Cash Flow
$5.03 per share
Book Value
$32.24 per share

Miscellaneous

Free Float
48,855,000
Market Cap
$3.46 billion
Optionable
Optionable
Beta
0.50
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report














PBH Stock Analysis - Frequently Asked Questions

Should I buy or sell Prestige Consumer Healthcare stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Prestige Consumer Healthcare in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" PBH shares.
View PBH analyst ratings
or view top-rated stocks.

What is Prestige Consumer Healthcare's stock price target for 2024?

2 brokers have issued twelve-month target prices for Prestige Consumer Healthcare's shares. Their PBH share price targets range from $103.00 to $117.00. On average, they predict the company's stock price to reach $110.00 in the next twelve months. This suggests a possible upside of 57.8% from the stock's current price.
View analysts price targets for PBH
or view top-rated stocks among Wall Street analysts.

How have PBH shares performed in 2024?

Prestige Consumer Healthcare's stock was trading at $61.22 at the beginning of the year. Since then, PBH stock has increased by 13.9% and is now trading at $69.72.
View the best growth stocks for 2024 here
.

Are investors shorting Prestige Consumer Healthcare?

Prestige Consumer Healthcare saw a increase in short interest in January. As of January 31st, there was short interest totaling 1,720,000 shares, an increase of 10.3% from the January 15th total of 1,560,000 shares. Based on an average daily volume of 228,700 shares, the short-interest ratio is presently 7.5 days. Currently, 3.5% of the shares of the stock are short sold.
View Prestige Consumer Healthcare's Short Interest
.

When is Prestige Consumer Healthcare's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our PBH earnings forecast
.

How were Prestige Consumer Healthcare's earnings last quarter?

Prestige Consumer Healthcare Inc. (NYSE:PBH) announced its quarterly earnings data on Thursday, February, 8th. The company reported $1.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.04 by $0.02. The business earned $282.74 million during the quarter, compared to analysts' expectations of $280.25 million. Prestige Consumer Healthcare had a positive trailing twelve-month return on equity of 14.09% and a negative net margin of 7.11%. The company's quarterly revenue was up 2.6% on a year-over-year basis. During the same quarter last year, the firm earned $1.04 earnings per share.

What guidance has Prestige Consumer Healthcare issued on next quarter's earnings?

Prestige Consumer Healthcare updated its FY 2024 earnings guidance on Thursday, February, 8th. The company provided EPS guidance of 4.330-4.330 for the period, compared to the consensus EPS estimate of 4.320. The company issued revenue guidance of $1.1 billion-$1.1 billion, compared to the consensus revenue estimate of $1.1 billion.

What is Ronald M. Lombardi's approval rating as Prestige Consumer Healthcare's CEO?

8 employees have rated Prestige Consumer Healthcare Chief Executive Officer Ronald M. Lombardi on Glassdoor.com. Ronald M. Lombardi has an approval rating of 61% among the company's employees. This puts Ronald M. Lombardi in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Prestige Consumer Healthcare own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Prestige Consumer Healthcare investors own include Pfizer (PFE), AbbVie (ABBV), Gilead Sciences (GILD), AT&T (T), Intel (INTC), ONEOK (OKE), Wells Fargo & Company (WFC), International Business Machines (IBM), Micron Technology (MU) and Teva Pharmaceutical Industries (TEVA).

Who are Prestige Consumer Healthcare's major shareholders?

Prestige Consumer Healthcare's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (11.59%), Dimensional Fund Advisors LP (6.92%), Westwood Holdings Group Inc. (2.27%), Allspring Global Investments Holdings LLC (2.10%), Massachusetts Financial Services Co. MA (2.09%) and Northern Trust Corp (1.47%). Insiders that own company stock include Mary Beth Fritz and Ronald M Lombardi.
View institutional ownership trends
.

How do I buy shares of Prestige Consumer Healthcare?

Shares of PBH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:PBH) was last updated on 2/24/2024 by MarketBeat.com Staff